Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTR5A | P47898 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 4/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 2/20 | 0.38 |
| ▸ | SI | P14410 | 2/20 | 0.38 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30101714 | 1.00 | GAA (0.47) | GAALMNAMAPTHTR5ABRD4 | |
| SCHEMBL21782466 | 0.86 | ACHE (0.43) | GAALMNAMAPTHTR5ABRD4 | |
| SCHEMBL7920989 | 0.86 | ACHE (0.43) | GAALMNAMAPTHTR5ABRD4 | |
| SCHEMBL30499354 | 0.81 | AR (0.40) | GAALMNAMAPTHTR5AAR | |
| SCHEMBL20911110 | 0.81 | AR (0.40) | GAALMNAMAPTHTR5ABRD4 | |
| SCHEMBL13091374 | 0.81 | AR (0.40) | GAALMNAMAPTHTR5AAR | |
| SCHEMBL21243002 | 0.81 | AR (0.40) | GAALMNAMAPTHTR5AAR | |
| SCHEMBL4133012 | 0.81 | AR (0.40) | GAALMNAMAPTHTR5AAR | |
| SCHEMBL12965849 | 0.80 | AR (0.45) | GAALMNAMAPTBRD4CREBBP | |
| SCHEMBL23788032 | 0.78 | HTR5A (0.38) | GAALMNAMAPTHTR5AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109161028-B | Preparation method of photodegradable two-dimensional polymer with cucurbituril as structural unit | 四川大学 | 2020-12-08 | — | — | CN | claimed |
| US-20260042748-A1 | AZETIDINE COMPOUNDS FOR TREATMENT OF HSV | ASSEMBLY BIOSCIENCES INC (US) | 2026-02-12 | — | — | US | disclosed |
| CN-116145156-A | Indoline compound preparation method based on organic electronic synthesis | 六盘水师范学院 | 2023-05-23 | — | — | CN | disclosed |
| CN-110437123-B | Method for synthesizing optically pure 2-substituted indoline compound through dynamic kinetic resolution | 华中师范大学 | 2023-01-03 | — | — | CN | disclosed |
| WO-2021083135-A1 | Bcl-2 INHIBITORS | BEIGENE, LTD. (KY) | 2021-05-06 | — | — | WO | disclosed |
| CN-107793371-B | Bromodomain recognition protein inhibitor and preparation method and application thereof | 中国科学院上海药物研究所 | 2020-12-15 | — | — | CN | disclosed |
| CN-109161028-B | Preparation method of photodegradable two-dimensional polymer with cucurbituril as structural unit | 四川大学 | 2020-12-08 | — | — | CN | disclosed |
| EP-3106453-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND, AND NOVEL METAL-DIAMINE COMPLEX | TAKASAGO PERFUMERY CO LTD (JP) | 2020-04-08 | — | — | EP | disclosed |
| CN-107793371-A | A kind of bromine domain identification protein inhibitor and its production and use | 中国科学院上海药物研究所 | 2018-03-13 | — | — | CN | disclosed |
| US-9745229-B2 | Method for producing optically active compound, and novel metal-diamine complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2017-08-29 | — | — | US | disclosed |
| US-20120010247-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-12 | — | — | US | disclosed |
| US-8012959-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2011-09-06 | — | — | US | disclosed |
| EP-2351743-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010050445-A1 | BICYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2010-05-06 | — | — | WO | disclosed |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | ASTELLAS PHARM INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090143381-A1 | MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-06-04 | — | — | US | disclosed |
| US-5047539-A | Ultraviolet radiation stabilizers | BASF AKTIENGESELLSCHAFT (DE) | 1991-09-10 | — | — | US | disclosed |
| EP-0399278-A2 | Heterocyclic amidine derivatives | BASF Aktiengesellschaft (DE) | 1990-11-28 | — | — | EP | disclosed |
| EP-0002721-B1 | PROCESS FOR PREPARING HYDRAZINES | BAYER AG (DE) | 1981-09-02 | — | — | EP | disclosed |
| EP-0002721-A2 | Process for preparing hydrazines | BAYER AG (DE) | 1979-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010247-A1 | BICYCLIC COMPOUND | ACACA, CPT1B, ACACB | GAA 1084/4885LMNA 1520/4885MAPT 3578/4885 |
| US-20260042748-A1 | AZETIDINE COMPOUNDS FOR TREATMENT OF HSV | CXCR1, ZC3HAV1L, ZC3HAV1 | GAA 768/4885LMNA 946/4885MAPT 4175/4885 |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | STAT6, STAT4, STAT3 | GAA 2744/4885LMNA 4695/4885MAPT 4703/4885 |
| US-20090143381-A1 | MODULATORS OF ATP-BINDING CASSETTE-TRANSPORTERS | CFTR, ABCB1, ABCC2 | GAA 387/4885LMNA 3826/4885MAPT 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.